Research across Embolism and Thrombosis
Related studies from across the Embolism and Thrombosis family.
35 trials tracked for venous thrombosis: 14 in phase 3 or 4 and 3 with published results. The most-cited published study has 771 citations.
Showing the 35 most-cited and recently-updated of 35 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Several anticoagulant agents have demonstrated efficacy in managing venous thromboembolism (VTE). Rivaroxaban significantly reduced the incidence of symptomatic recurrent VTE compared to other treatments 12 and showed a reduction in the composite of recurrent DVT, non-fatal PE, and all-cause mortality 12. BAY 59-7939 also demonstrated significant reductions in the composite of fatal or non-fatal symptomatic recurrent VTE 3, as well as in the composite of primary efficacy outcomes including myocardial infarction, ischemic stroke, or systemic non-CNS embolism 3.
Fondaparinux has shown consistent results in reducing VTE events and mortality [13, 14] and demonstrated a 0% rate of recurrent or new symptomatic VTE in specific cohorts 15. Edoxaban tosylate was associated with significantly lower rates of clinically relevant bleeding compared to other treatments 7, while Apixaban showed significant reductions in the composite of symptomatic recurrent VTE or all-cause death 10. Enoxaparin also demonstrated a statistically significant reduction in the incidence of adjudicated composite symptomatic, recurrent VTE or VTE-related death 9.
recent-not-corroborated":["JETi for lower extremity venous thrombosis showed an 84.5% success rate for $\geq$75% thrombus reduction with a 1.7% rate of major adverse events within 30 days 1."],
AI synthesis of 7 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Embolism and Thrombosis family.